AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25294250
Drug: Vancomycin (7-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (7-10 days of twice-daily treatment)
Trial: 9375539
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg methylprednisolone (MP)
Trial: 7672489
Drug: Subcutaneous fast‐acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fast‐acting insulin
Trial: 24693632
Drug: NaF-DL combination
RxNorm normalized name: DL-dimyristoylphosphatidylcholine
DrugBank: DL-dimyristoylphosphatidylcholine (DB11283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF-DL combination
Trial: 24693632
Drug: HEMA-G (Gluma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEMA-G (Gluma desensitizer)
Trial: 21813162
Drug: warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin plus 75‐100 mg aspirin
Trial: 21813162
Drug: warfarin only
RxNorm normalized name: Warfarin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin only
Trial: 3830930
Drug: L-tryptophan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (1 g with 10 g of CHO, three times a day, 30 min before meals)
Trial: 18391631
Drug: Chemotherapy regimens:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens: Methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine and cisplatin
Trial: 11908598
Drug: Oleoresin capsicum
RxNorm normalized name: Oleoresin capsicum
DrugBank: Capsicum oleoresin (DB11131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleoresin capsicum (OC) spray inhalation
Trial: 8585252
Drug: Midazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (mean 4.8 mg) plus pethidin (50 mg)
Trial: 8585252
Drug: Midazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (mean 5.2 mg i.v.)
Trial: 2615928
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of d-amphetamine sulfate
Trial: 31331546
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum perforatum (St John's wort) 270‐330 μg tablets three times a day for two months
Trial: 29950814
Drug: Verinurad 10
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 10 mg (multiple doses)
Trial: 29950814
Drug: Verinurad (2.5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad (2.5-15 mg, single and multiple doses)
Trial: 22238097
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 4 mg of cortisol (hydrocortisone)
Trial: 9636831
Drug: G-CSF (filgrastim)-supported
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (filgrastim)-supported FEC therapy (5-fluorouracil, epirubicin, and cyclophosphamide) with ciprofloxacin prophylaxis; nine courses q three weeks; six different FEC dose levels used for treatment.
Trial: 2962005
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg daily)
Trial: 29452970
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatments (CGC, CMC, HPG)
Trial: 22510538
Drug: Morphine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (60 mg/day) + Pregabalin (25 mg/day to 150 mg/day over one week)
Trial: 18026891
Drug: Risperidone (0.01-0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.01-0.08 mg/kg/day)
Trial: 15345500
Drug: AZD3582 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3582 750 mg twice daily
Trial: 16497612
Drug: AZD3582 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3582 750 mg daily
Trial: 16497612
Drug: naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 250 mg twice daily
Trial: 11119080
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (INO) at 4 ppm
Trial: 11969277
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg intravenous bolus, then 40 mg subcutaneously every 8 h)
Trial: 2756913
Drug: High-energy supplement
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy supplement
Trial: 2756913
Drug: Low-energy supplement
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy supplement
Trial: 5320587
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment with griseofulvin
Trial: 5320587
Drug: Hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital treatment with griseofulvin
Trial: 31637971
Drug: Baseline albuminuria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline albuminuria (≥30 mg/g) versus not
Trial: 12457078
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day for 28 days followed by 10 mg/day)
Trial: 10749249
Drug: Fractal analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractal analysis of nuclear medicine images
Trial: 3710634
Drug: Rapidly dissolving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapidly dissolving tablet (1.0 g)
Trial: 3710634
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release product C (1.0 g)
Trial: 3710634
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release product D (1.0 g)
Trial: 29457540
Drug: High CD34+
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CD34+ cell dosage
Trial: 6797863
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 40.3 ± 2.0 kcal.kg‐1.day‐1 (7.0 mg glucose.kg‐1.min‐1) and 0.27 ± 0.02 g N.kg‐1.day‐1
Trial: 6797863
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: 53.4 ± 6.8 kcal.kg‐1.day‐1 (9.2 mg glucose.kg‐1.min‐1) and 0.36 ± 0.05 g N.kg‐1.day‐1
Trial: 29275370
Drug: Programmable Hypertension
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmable Hypertension Control (PHC) therapy activated after baseline measurements
Trial: 18662829
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravitreal triamcinolone
Trial: 17905097
Drug: Intravesical botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical botulinum toxin A (BTX‐A) injections (100 U or 200 U) followed by cystoscopic hydrodistension
Trial: 17905097
Drug: Intravesical botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical botulinum toxin A (BTX‐A) injections
Trial: 29141255
Drug: Nortriptyline (NOR)
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline (NOR) 50-150 mg (mean dose 106.2, SD±8.2)
Trial: 29141255
Drug: Venlafaxine (VEN)
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine (VEN) 75-225 mg (mean dose 181.3, SD±8.8)
Trial: 23944720
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg QD plus PegIFN/RBV
Trial: 23944720
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD plus PegIFN/RBV
Trial: 23944720
Drug: Faldaprevir 240
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 240 mg QD plus PegIFN/RBV (treatment-experienced)
Trial: 22357699
Drug: No CKD
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No CKD (eGFR ≥ 60 mL/min)
Trial: 24299019
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg/day)
Trial: 1691921
Drug: Cisplatin 120
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 120 mg m‐2 on days 1 and 29 and vindesine 3 mg m‐2 weekly x 6
Trial: 1691921
Drug: Cisplatin 120
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 120 mg m‐2 on days 1 and 29 and vindesine 3 mg m‐2 weekly x 6 (for patients without dissemination)
Trial: 1691921
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (for patients without dissemination)
Trial: 19432567
Drug: Iron supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplement (60 mg daily)
Trial: 11840040
Drug: Interferon-alpha +
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha + Ribavirin (3 million U/m2 subcutaneous interferon-alpha three times weekly and 15 mg/kg oral ribavirin daily for 12 months)
Trial: 11840040
Drug: Interferon-alpha (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (3 million U/m2 subcutaneous interferon-alpha three times weekly for 12 months)
Trial: 23129180
Drug: Alfacalcidol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1.0 μg daily)
Trial: 17477111
Drug: Drospirenone/estradiol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone/estradiol therapy
Trial: 2205798
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (8.7 mumol or 8333 IU) and Vitamin E (46 mumol or 20 mg)
Trial: 6788458
Drug: Ceftriaxone Ro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone Ro 13-9904, 250 mg
Trial: 27554534
Drug: Rabivax-S (1mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabivax-S (1mL IM; five doses)
Trial: 27554534
Drug: Rabivax-S (0.1mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabivax-S (0.1mL ID; eight doses)
Trial: 27554534
Drug: Purified chick
RxNorm normalized name: rabies vaccine, purified chick embryo cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified chick embryo cell vaccine (PCEC, Rabipur®) (1mL IM; five doses)
Trial: 9250846
Drug: Enoxaparin (low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (low-molecular-weight heparin)
Trial: 17601186
Drug: Antiparkinsonian medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparkinsonian medication (presurgery dosage)
Trial: 8135445
Drug: Slow-release sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release sodium fluoride (25 mg twice daily) with continuous calcium citrate (400 mg calcium twice daily)
Trial: 8135445
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with continuous calcium citrate (400 mg calcium twice daily)
Trial: 1093389
Drug: Bivalent measles-rubella
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent measles-rubella vaccine
Trial: 31397969
Drug: Desmopressin ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin ODT 25 μg
Trial: 31397969
Drug: Desmopressin ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin ODT 25 μg (females)
Trial: 22415421
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment with 40 mg/day of proton pump inhibitors (PPIs)
Trial: 22415421
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (Nissen fundoplication, NFP)
Trial: 20306184
Drug: Pantoprazole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 2.5 mg (approx. 1.2 mg/kg)
Trial: 2029014
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (500 mg three times a day) with low sodium diet
Trial: 7024762
Drug: des‐phe‐mixed‐insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: des‐phe‐mixed‐insulin
Trial: 7024762
Drug: Mixtard (highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixtard (highly purified insulin from pig)
Trial: 24664788
Drug: 40% L-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% L-menthol
Trial: 24664788
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L-menthol and CA
Trial: 1553769
Drug: Cololax regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cololax regimen (oral ingestion of electrolyte polyethylene glycol solution)
Trial: 26011549
Drug: Tailored behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored behavioral pharmacist‐administered and telephone‐based intervention (CITIES)
Trial: 26400431
Drug: Delphinol (maqui
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delphinol (maqui berry extract) 162 mg anthocyanins, taken 3 times daily for 4 weeks
Trial: 17454589
Drug: IFNalpha‐2a, 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNalpha‐2a, 9 MIU once daily
Trial: 17454589
Drug: PEG‐IFNalpha‐2a, 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNalpha‐2a, 450 microg once weekly
Trial: 12414849
Drug: 1 mg/d
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/d micronized E(2) (n = 12)
Trial: 7857585
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and ridazolol (beta-adrenoreceptor blockers)
Trial: 26
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Sch 1000
Trial: 21981869
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules containing 3g of wheat flour each, taken morning and evening)
Trial: 19019594
Drug: Oleoresin capsicum
RxNorm normalized name: Oleoresin capsicum
DrugBank: Capsicum oleoresin (DB11131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleoresin capsicum (O.C.) (5-s spray to the eyes)
Trial: 15377853
Drug: Subjective burden
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective burden before adjuvant therapy
Trial: 11865786
Drug: EMLA anesthetic
RxNorm normalized name: Emla Anesthetic Disc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA anesthetic cream applied for 15 minutes
Trial: 8163732
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg DMSA for 14 days
Trial: 8163732
Drug: DMSA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSA treatment
Trial: 2828406
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (20 mg/kg)
Trial: 2828406
Drug: Cortisol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (0.1 mg/kg)
Trial: 2828406
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 and cortisol combination
Trial: 25840429
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (400 mcg) 1 hour prior to surgery
Trial: 25840429
Drug: Administration route
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration route
Trial: 19728565
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of 135 mg amodiaquine and 50 mg artesunate administered after a high-fat breakfast
Trial: 19728565
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of 135 mg amodiaquine and 50 mg artesunate administered in fasting state
Trial: 15705369
Drug: GnRH-agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH-agonist
Trial: 10201465
Drug: Omeprazole 80
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 80 mg q.d. and metronidazole extended‐release formulation 750 mg q.d. for 10 days (OM)
Trial: 10201465
Drug: OM plus
RxNorm normalized name: Childrens Multi-symptom Plus Cough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM plus clarithromycin 1 g q.d. for 10 days (OMCI)
Trial: 7575985
Drug: Low air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low air loss (LAL) therapy
Trial: 3102089
Drug: Ifosfamide (IFOS)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide (IFOS) 5 g/m2
Trial: 3102089
Drug: Cyclophosphamide (CYCLO)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CYCLO) 1.5 g/m2
Trial: 26331711
Drug: Pre-ESD eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ESD eradication therapy (n = 44)
Trial: 26331711
Drug: Post-ESD eradication
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-ESD eradication therapy (n = 52)
Trial: 12770651
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and postoperative administration of atenolol
Trial: 10894377
Drug: Core decompression
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Core decompression (surgical treatment)
Trial: 11567544
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (control group)
Trial: 8336255
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid treatment (saturated, pH 1 for 3 minutes)
Trial: 29193548
Drug: Pre-hospital blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hospital blood product (PHBP) administration (up to two units of red blood cells and two units of lyophilised plasma)
Trial: 29193548
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (up to four boluses of 250 mL 0.9% saline)
Trial: 9065279
Drug: Preoperative hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative hormone therapy
Trial: 9065279
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative hormone therapy (Control)
Trial: 1860293
Drug: Topical varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical varnish containing strontium chloride
Trial: 28062251
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (0.7ng/ml target-controlled infusion)
Trial: 25613351
Drug: Bilateral subthalamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subthalamic nucleus (STN) DBS + Optimal Drug Therapy (ODT)
Trial: 23083831
Drug: Dinoprostone intravaginal
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dinoprostone intravaginal suppository
Trial: 21457679
Drug: TAU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU plus brief behavioral therapy for insomnia (4 weekly 1-hour sessions)
Trial: 30153781
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care fluid administration
Trial: 1518731
Drug: Ibuprofen 1800
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 1800 mg/day for 6 days
Trial: 31809216
Drug: AR19 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR19 20 mg
Trial: 30722001
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 μg)
Trial: 30722001
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL 0.9% saline)
Trial: 22280352
Drug: 12 μg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 μg/die of vitamin K (G II)
Trial: 22280352
Drug: Placebo (G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (G III)
Trial: 20164823
Drug: Erythropoietin (high-dose);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (high-dose); administered based on biomarker levels above 46.3
Trial: 18757324
Drug: Weight change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight change during adjuvant therapy
Trial: 2142949
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) - 50 micrograms bolus, then 1 microgram/min infusion